Dr. Elena Rizova
Vice President World-Wide Medical Dupixent at Sanofi

“I collaborated with Prof T. Bieber for several years in the context of the development, approval and introduction of new therapies in the field of dermatology, allergy and immune inflammation. His expertise as researcher, clinician augmented by his regulatory affairs competencies has been of tremendous support. Prof T. Bieber has provided a very valuable and unique contribution to the expansion of the clinical development of dupilumab in the field of dermatology and immune inflammation.

Prof T. Bieber has the unique capacity of understanding the basic science, clinical aspect of the disease and requirements from the regulatory authorities. He is passionate about science but very disciplined and organized in his professional approach. His leadership and professionalism is well known among the pharmaceutical industry professionals which make him unique when it comes to scientific advice. I have always appreciated his honest, open-minded and professional work style. I am recommending him as partner and advisor for variety of projects from basic research to registration and introduction of novel therapies in the treatment paradigm.”

Prof. Jacob Thyssen
CSO and EVP in LEO Pharma

“I have (co-)worked with Professor Bieber on multiple occasions in the past 10 years as a dermatology consultant for pharmaceutical industry. Professor Bieber holds the highest level of international expertise in the field regarding inflammatory skin disease, and I have worked with him on all aspects, from trial designs, trial read outs, strategic positioning to regulatory recommendations. Professor Biebers depth of insight is remarkable, and he is an innovative and logical thinker, a strategist and a consummate team player. I will not hesitate to employ Professor Bieber for any consultancy task in dermatology in my new role as CSO and EVP in LEO Pharma.”

Dr. Peter Lichtlen
CMO Numab Therapeutics AG

“We work with Dr. Bieber for almost two years. Thomas has been an extremely valuable resource for our innovative bispecific antibody program in atopic dermatitis. Thomas brings a unique combination of scientific, clinical and pharmacological expertise combined with deep understanding of the regulatory framework and the continuously evolving pricing and reimbursement environment. As a small biotech with ambitious plans in the field of immune-mediated diseases, Thomas is the perfect partner to ensure our clinical development programs are set up for success and to the benefit of patients.”

Dr. Wouter Eijkelkamp
Medical Director, Micreos

“Leveraging his unique blend of clinical expertise, in-depth knowledge of immunology, coupled with a very solid understanding of regulatory affairs, Pr. Bieber at BDC played a key role in conceiving the clinical development program.”

Dr. Urs Kerckmann
VP and Team Lead Global Medical Affairs Dermatology, Pfizer

“With his profound clinical and research experience in the areas of Dermatology and Immunology Prof. Bieber is one of the key global experts for various matters during the lifecycle of drug development. Moreover he owns additional deep expertise in regulatory drug development aspects as well as market access questions which makes consultancies with him even more fruitful for pharmaceutical companies. But maybe even more important, on a personal level he is also a very pleasant collaborator.”

Helena Agell Gimeno
Lebrikizumab Global Medical Manager at Almirall

„Prof Thomas Bieber’s is an expert and reference on the field of atopic dermatitis: his clinical expertise, combined with a deep knowledge on immunology, and as well understanding of regulatory and market access frameworks across Europe and beyond allow him to provide unique strategic insights. He is not only an outstanding professional but also a great person. We have worked with him and will continue to do so in the coming years“.